WMFT, I really can't understand why you're laughing about a infringement suit against CDEX. Don't blow this off as trivial, remember that Mckesson is the one that has the exclusive right's to the technology.
Mckesson wanted right's to the ASD tech real bad and it appears as if they want to protect a market which they obviously believe is theirs.
Mckesson started placement of the validation technology at high-end, central fill locations, but must recognize the market potential of low cost units as well.
By: diddy
19 Jan 2005, 01:48 PM EST
Msg. 229610 of 239409
Jump to msg. #
BTW, I have confirmed the following:
1. Spectral fingerprint validation systems are already in operation across America in pharmaceutical central fill locations. This is where orders are filled and meds are sent to hospital pharmacies and chain store outlets such as Walmart.
2. Cardinal Healthcare and McKesson Pharmaceuticals had a bidding war for the systems. McKesson won. Contracts are on-going.
How this plays out with Valimed I have no idea, but it appears that CDEX is intentionally starting at the opposite end of the supply chain. Don't make no sense tryin' to butt heads with the big boys.
diddy
McKesson Corporation is the leading provider of supply, information and care management products and services designed to reduce costs and improve quality across healthcare. McKesson solutions empower healthcare professionals with the tools they need to deliver care more effectively and efficiently. Founded in 1833, with annual revenues of more than $50 billion, McKesson ranks as the 16th largest industrial company in the United States.
